← All trials
NCT06128837
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jun 30, 2028
- Completion date
- Oct 31, 2028
- First posted
- Nov 13, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 686
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Luye PharmaLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.